AstraZeneca Plc’s Covid-19 antibody drug likely won’t work against an ascendant new variant, the US Food and Drug Administration said Friday, leaving high-risk people with fewer protections as mutations mount. The variant, known as XBB.1.5, is the latest to wallop the US and now accounts for more than a quarter of US Covid cases. AstraZeneca’s antibody drug, Evusheld, was the last of its kind still authorized to prevent infections in high-risk people. Antibody therapies have been essential for treating and preventing disease in roughly 7 million immunocompromised Americans for whom vaccines and antivirals can be less effective. But Covid has continued to mutate, knocking antibody drugs off the market one-by-one. Stay with TOI for live updates-
Posted from: this blog via Microsoft Power Automate.